- Home
- NRIX vs AC Comparison
NRIX vs AC Comparison
Compare NRIX & AC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- AC
- Stock Information
- Founded
- NRIX 2009
- AC 1976
- Country
- NRIX United States
- AC United States
- Employees
- NRIX N/A
- AC N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- AC Investment Bankers/Brokers/Service
- Sector
- NRIX Health Care
- AC Finance
- Exchange
- NRIX Nasdaq
- AC Nasdaq
- Market Cap
- NRIX 766.0M
- AC 787.6M
- IPO Year
- NRIX 2020
- AC N/A
- Fundamental
- Price
- NRIX $10.56
- AC $36.68
- Analyst Decision
- NRIX Strong Buy
- AC
- Analyst Count
- NRIX 15
- AC 0
- Target Price
- NRIX $29.13
- AC N/A
- AVG Volume (30 Days)
- NRIX 678.5K
- AC 5.0K
- Earning Date
- NRIX 10-10-2025
- AC 08-06-2025
- Dividend Yield
- NRIX N/A
- AC 0.54%
- EPS Growth
- NRIX N/A
- AC 64.87
- EPS
- NRIX N/A
- AC 2.54
- Revenue
- NRIX $88,381,000.00
- AC $11,905,000.00
- Revenue This Year
- NRIX $71.51
- AC N/A
- Revenue Next Year
- NRIX N/A
- AC N/A
- P/E Ratio
- NRIX N/A
- AC $14.52
- Revenue Growth
- NRIX 41.86
- AC N/A
- 52 Week Low
- NRIX $8.18
- AC $29.18
- 52 Week High
- NRIX $29.56
- AC $43.85
- Technical
- Relative Strength Index (RSI)
- NRIX 43.38
- AC 46.33
- Support Level
- NRIX $9.44
- AC $36.56
- Resistance Level
- NRIX $10.98
- AC $37.01
- Average True Range (ATR)
- NRIX 0.57
- AC 0.54
- MACD
- NRIX -0.08
- AC -0.01
- Stochastic Oscillator
- NRIX 38.75
- AC 74.34
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About AC Associated Capital Group Inc.
Associated Capital Group Inc is a diversified financial services company. It operates in the business of alternative investment management, institutional research services, and cash and other assets through subsidiaries. The activities of its subsidiaries comprise publishing daily research notes and full reports using private market value with a catalyst methodology and also products and customized solutions utilizing private market value with catalyst method of investing.